Cargando…

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

Objective: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). Methods: Outpatient children (7–11 years) and adolescents (12–17 years) who met DSM-IV-TR criteria for MDD and had screening a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atkinson, Sarah, Lubaczewski, Shannon, Ramaker, Sara, England, Richard D., Wajsbrot, Dalia B., Abbas, Richat, Findling, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771531/ https://www.ncbi.nlm.nih.gov/pubmed/29185786 http://dx.doi.org/10.1089/cap.2017.0099

Ejemplares similares

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
por: Weihs, Karen L., et al.
Publicado: (2018)

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
por: Katzman, Martin A., et al.
Publicado: (2017)

Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009)

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression
por: Zilcha-Mano, Sigal, et al.
Publicado: (2021)

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
por: Lieberman, Daniel Z, et al.
Publicado: (2010)

Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine
por: Benoit, James R.A., et al.
Publicado: (2021)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

A Comparative Study on Safety and Efficacy of Desvenlafaxine Versus Sertraline in Depression
por: Ch, Saritha, et al.
Publicado: (2022)

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder
por: Liebowitz, Michael R, et al.
Publicado: (2013)

Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study
por: Roh, Sungwon, et al.
Publicado: (2022)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
por: Durgam, Suresh, et al.
Publicado: (2018)

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
por: Lyndon, Gavin J., et al.
Publicado: (2019)

PS210. Effect of Desvenlafaxine on Altered Heart Rate Variability in Persistent Depressive Disorder
por: Ravindran, Arun V., et al.
Publicado: (2016)

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
por: Soares, Claudio N., et al.
Publicado: (2019)

PS100. Open-label Desvenlafaxine as Monotherapy for Persistent Depression Disorder: A Pilot Study
por: Ravindran, Arun V., et al.
Publicado: (2016)

Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial
por: Gupta, Brij Mohan, et al.
Publicado: (2016)

A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up
por: Findling, Robert L., et al.
Publicado: (2020)

Periodontal status in chronic periodontitis depressed patients on desvenlafaxine: An observational study
por: Bhatia, Anu, et al.
Publicado: (2018)

Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression
por: ZAMANIAN, Abbas, et al.
Publicado: (2017)

Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study
por: Wigal, Sharon B., et al.
Publicado: (2018)

Desvenlafaxine Extended-Release in Panic Disorder: A Retrospective Chart Review
por: Min Lee, Sang, et al.
Publicado: (2022)

Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
por: Bousman, Chad A., et al.
Publicado: (2017)

Venlafaxine and desvenlafaxine in the management of menopausal hot flashes
por: Johnson, Emily D, et al.
Publicado: (2011)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
por: Fu, Dong-Jing, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial
por: Mahajan, Sonia Shinde, et al.
Publicado: (2019)

Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
por: Umland, Elena M, et al.
Publicado: (2012)

Drug–drug interactions involving antidepressants: focus on desvenlafaxine
por: Low, Yvette, et al.
Publicado: (2018)

Desvenlafaxine-Induced Interstitial Pneumonitis: A Case Report
por: Flora, Arjan, et al.
Publicado: (2018)

Multidisciplinar treatment in postpartum depression. Coordinated attention of psychiatrist and midwife: use of desvenlafaxine while breastfeeding
por: Sánchez Rus, S.S., et al.
Publicado: (2022)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Prenatal desvenlafaxine induced behavioural alterations in Swiss albino mice
por: Kumari, Amrita, et al.
Publicado: (2014)

Desvenlafaxine-associated hyperglycemia: A case report and literature review
por: Mekonnen, Andrea D., et al.
Publicado: (2020)

Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets
por: Carapeto, Gustavo Vaiano, et al.
Publicado: (2023)

The Ethics of Prescription of Placebos to Patients with Major Depressive Disorder
por: Chua, Shun-Jie, et al.
Publicado: (2015)

Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials
por: Cohen, David, et al.
Publicado: (2008)

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
por: Maity, Nabakumar, et al.
Publicado: (2014)

Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy
por: Allen, Rob, et al.
Publicado: (2014)

LC–UV and LC–MS evaluation of stress degradation behavior of desvenlafaxine
por: Pawar, Shubhangi M., et al.
Publicado: (2012)

Hybrid polymeric matrices for oral modified release of Desvenlafaxine succinate tablets
por: Samy, Wael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_iu9d4rnrj3lplfl3rkuqam1iuc